Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study

医学 贝伐单抗 肝细胞癌 内科学 阿替唑单抗 胃肠病学 肿瘤科 癌症 化疗 免疫疗法 彭布罗利珠单抗
作者
Kazunari Tanaka,Kunihiko Tsuji,Atsushi Hiraoka,Toshifumi Tada,Masashi Hirooka,Kazuya Kariyama,Joji Tani,Masanori Atsukawa,Koichi Takaguchi,Ei Itobayashi,Shinya Fukunishi,Toru Ishikawa,Kazuto Tajiri,Hironori Ochi,Hidenori Toyoda,Chikara Ogawa,Takashi Nishimura,Takeshi Hatanaka,Satoru Kakizaki,Noritomo Shimada
出处
期刊:Cancers [Multidisciplinary Digital Publishing Institute]
卷期号:15 (17): 4348-4348 被引量:17
标识
DOI:10.3390/cancers15174348
摘要

Aim: This study aimed to evaluate the ability of a previously reported tumor marker (TM) score involving alpha-fetoprotein (AFP), fucosylated AFP (AFP-L3), and des gamma-carboxy prothrombin (DCP) as TMs in predicting the prognosis and therapeutic efficacy in hepatocellular carcinoma (HCC) patients administered atezolizumab plus bevacizumab (Atez/Bev) as first-line treatment. Materials/Methods: The study period covered September 2020 to December 2022 and involved 371 HCC patients treated with Atez/Bev. The values of the TMs AFP, AFP-L3, and DCP were measured upon introducing Atez/Bev. Elevations in the values of AFP (≥100 ng/mL), AFP-L3 (≥10%), and DCP (≥100 mAU/mL) were considered to indicate a positive TM. The number of positive TMs was summed up and used as the TM score, as previously proposed. Hepatic reserve function was assessed using the modified albumin–bilirubin grade (mALBI). Predictive values for prognosis were evaluated retrospectively. Results: A TM score of 0 was shown in 81 HCC patients (21.8%), 1 in 110 (29.6%), 2 in 112 (29.9%), and 3 in 68 (18.3%). The median overall survival (OS) times for TM scores 0, 1, 2, and 3 were not applicable [NA] (95% CI NA-NA), 24.0 months (95% CI 17.8-NA), 16.7 months (95% CI 17.8-NA), and NA (95% CI 8.3-NA), respectively (p < 0.001). The median progression-free survival (PFS) times for TM scores 0, 1, 2, and 3 were 16.5 months (95% CI 8.0-not applicable [NA]), 13.8 months (95% CI 10.6–21.3), 7.7 months (95% CI 5.3–8.9), and 5.8 months (95% CI 3.0–7.6), respectively (p < 0.001). OS was well stratified in mALBI 1/2a and mALBI 2a/2b. PFS was well stratified in mALBI 2a/2b, but not in mALBI 1/2a. Conclusions: The TM score involving AFP, AFP-L3, and DCP as TMs was useful in predicting the prognosis and therapeutic efficacy in terms of OS and PFS in HCC patients administered Atez/Bev as first-line treatment.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
彭于晏的应助被unicornmed采纳,获得10
刚刚
复杂的悟空完成签到,获得积分10
刚刚
Alexlovar完成签到,获得积分20
1秒前
3秒前
Alicyclobacillus完成签到,获得积分10
4秒前
我爱科研科研爱我完成签到,获得积分10
7秒前
8秒前
小蘑菇的应助被陈小黑采纳,获得10
8秒前
9秒前
ly完成签到,获得积分10
9秒前
10秒前
ref:rain完成签到 ,获得积分10
11秒前
杨淼发布了新的文献求助10
12秒前
饼大王完成签到,获得积分10
13秒前
14秒前
14秒前
一切顺利发布了新的文献求助10
14秒前
HY完成签到,获得积分10
14秒前
Gyqqqq发布了新的文献求助10
14秒前
inoo完成签到 ,获得积分10
15秒前
15秒前
16秒前
搜集达人的应助被xiang采纳,获得10
16秒前
wzy完成签到,获得积分10
17秒前
科目三的应助被明前易拉罐采纳,获得10
17秒前
MADAO发布了新的文献求助30
17秒前
18秒前
嗷嗷ao发布了新的文献求助10
18秒前
简单的浩然关注了科研通微信公众号
18秒前
哈哈嘿完成签到,获得积分10
19秒前
20秒前
千凡发布了新的文献求助10
21秒前
异乡人发布了新的文献求助10
21秒前
四月完成签到,获得积分10
21秒前
调皮的醉山完成签到 ,获得积分10
21秒前
21秒前
9527发布了新的文献求助10
22秒前
LL关闭了LL的文献求助
22秒前
一切顺利完成签到,获得积分10
23秒前
MARIO完成签到 ,获得积分10
23秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181839
求助须知:如何正确求助?哪些是违规求助? 9571584
关于积分的说明 21818707
捐赠科研通 7778124
什么是DOI,文献DOI怎么找? 3433524
关于科研通互助平台的介绍 2557710
邀请新用户注册赠送积分活动 2479621